Relationship Between Brain-derived Neurotrogphic Factor (bdnf) And The Effects Of Antidepressants

PartⅠThe relationship between BDNF gene and the effects of antidepressantsObjective:To investigator the relationship between BDNF gene and the effects of antidepressants.Methods:A total 147 patients with MDD (DSM-IV criteria) were recruited from Dec.2005 to Dec.2009. The participants were administrated regularly 6 weeks antidepressant treatment. The endpoint effects of antidepressants, including clinical remission (HAMD17≤7) and response (decreased rate of HAMD17≥50%), were assessed by HAMD. The BDNF Val66Met and C270T polymorphisms were genetyped from sampled venous blood.Results:(1) It was found that female patients with C alleltype of C270T polymorphisms would have more opportunities (p<0.05) to get clinical remission when compared clinical remission group (n=81) with clinical non-remission group (n=66). (2) It was found that patients with G/G or A/A of Val66Met polymorphisms would have more opportunities (p< 0.05) to get clinical response when compared reponse group (n=123) with non-response group (n=24). (3) There was no statistically significant difference between three groups per genetype (32 patients with G/G,89 patients with G/A, and 26 patients with A/A) in clinical rating scales, including HAMD, HAMA, CGI-S and CGI-I (p>0.05).Conclusions:(1) It seems like that BDNF Val66Met polymorphism would have association with clinical response of antidepressants. The paitents with G/G or A/A of Val66Met would have some advantages in response. (2) It seems like that BDNF C270T polymorphism in female patients would have association with clinical remission of antidepressants. The female patients with C alleltype would have some advantages in remission. PartⅡThe relationship between serum BDNF level and the effects of antidepressantsObjective:To investigator the relationship between serum BDNF levels and the effects of antidepressants.Methods:A total 61 patients with MDD (DSM-Ⅳcriteria) were recruited from Dec.2006 to Dec.2009. The participants were administrated regularly 8 weeks antidepressant paroxetine treatment. The endpoint effects of antidepressants, including clinical remission (HAMD17≤7) and response (decreased rate of HAMD17≥50%), were assessed by HAMD. The serum BDNF levels were examined before and after treatment (week 2, week 4 and week 8) from sampled venous blood.Results:(1) It was found that overall statistical significance among 4 sampling time (p=0.003). There was no statistically significant difference between serum BDNF levels at week 2 and that of before treatment (p>0.05), however, there were statistically significant increasing levels at week 4 and week 8 comparing with that of before treatment (p=0.001, p=0.003). (2) There was no correlation between serum BDNF levels and measurement for effects of antidepressants, including HAMD, HAMA, CGI-S and CGI-I. (3) There was no statistically significant difference between clinical remission group (n=31) and clinical non-remission group (n=30) (p>0.05), although the previous group's serum BDNF levels were always high than that of later group. (4) There was no statistically significant difference between response patients (n=45) and non-response patients (n=16) (p>0.05), although the values of previous group's serum BDNF were always high than that of later group.Conclusions:(1) Serum BDNF levels were consistently increasing along with administration of antidepressants. (2) In general, it would not find correlation between serum BDNF levels and the effects of antidepressants.